

- 41 -

Claims

1. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol, which represents a sulfonate salt or a free base form.
2. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form I, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of $7.1^{\circ} \pm 0.2^{\circ}$, $12.9^{\circ} \pm 0.2^{\circ}$, $15.4^{\circ} \pm 0.2^{\circ}$, $18.2^{\circ} \pm 0.2^{\circ}$ and/or $21.2^{\circ} \pm 0.2^{\circ}$.
3. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form II, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of $7.8^{\circ} \pm 0.2^{\circ}$, $15.0^{\circ} \pm 0.2^{\circ}$, $17.6^{\circ} \pm 0.2^{\circ}$, $20.7^{\circ} \pm 0.2^{\circ}$ and/or $23.3^{\circ} \pm 0.2^{\circ}$.
4. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form III, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of $10.2^{\circ} \pm 0.2^{\circ}$, $13.8^{\circ} \pm 0.2^{\circ}$, $15.1^{\circ} \pm 0.2^{\circ}$, $18.8^{\circ} \pm 0.2^{\circ}$ and/or $19.9^{\circ} \pm 0.2^{\circ}$.
5. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form IV, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of $6.9^{\circ} \pm 0.2^{\circ}$, $12.6^{\circ} \pm 0.2^{\circ}$, $15.0^{\circ} \pm 0.2^{\circ}$, $15.7^{\circ} \pm 0.2^{\circ}$ and/or $22.2^{\circ} \pm 0.2^{\circ}$.

- 42 -

6. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form V, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of $6.9^{\circ} \pm 0.2^{\circ}$, $15.7^{\circ} \pm 0.2^{\circ}$, $17.5^{\circ} \pm 0.2^{\circ}$, $22.2^{\circ} \pm 0.2^{\circ}$ and/or $25.4^{\circ} \pm 0.2^{\circ}$.
7. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form VI, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) $6.7^{\circ} \pm 0.2^{\circ}$, $9.3^{\circ} \pm 0.2^{\circ}$, $16.1^{\circ} \pm 0.2^{\circ}$, $19.4^{\circ} \pm 0.2^{\circ}$ and/or $25.0^{\circ} \pm 0.2^{\circ}$.
8. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form VII, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of $6.7^{\circ} \pm 0.2^{\circ}$, $9.9^{\circ} \pm 0.2^{\circ}$, $16.3^{\circ} \pm 0.2^{\circ}$, $19.1^{\circ} \pm 0.2^{\circ}$, and/or $24.3^{\circ} \pm 0.2^{\circ}$.
9. A crystalline compound according to any of claims 1 to 8 for use as a medicament.
10. A crystalline compound according to any of claims 1 to 8 for use in the treatment and/or prevention of a parasitic infection, wherein the parasitic infection is preferably malaria, or a parasitic infection caused by plasmodium species.
11. A pharmaceutical composition comprising a therapeutically effective amount of at least one crystalline compound according to any of claims 1 to 8, wherein the pharmaceutical composition preferably comprises a therapeutically effective amount of second pharmacologically active substance, and wherein pharmacologically active substance is preferably an antimalarial.

- 43 -

12. A pharmaceutical composition according to claim 11 further comprising at least one additional compound selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, diluents, carriers and/or additional pharmaceutically active substances other than the compounds according to any of claims 1 to 8.

13. Kit comprising a therapeutically effective amount of at least one crystalline compound according to any of claims 1 to 8 and/or at least one pharmaceutical composition as claimed in any of claims 11 or 12 and a therapeutically effective amount of at least one further pharmacologically active substance other than the crystalline compounds as claimed in any of claims 1 to 8, wherein the further is preferably an antimalarial agent.

14. A method for treating and/or preventing, comprising administering to a human in need of such a treatment a therapeutically effective amount of crystalline compound according to any of claims 1 to 8.

15. Process for manufacturing of a crystalline modification according to any of claims 1 to 8.